Back to search

University of British Columbia

Opioid agonist therapy under the PharmaCare psychiatric medications plan : utilization, retention, and financial consequences

Abstract

dc:description

Background – Opioid Agonist Therapy (OAT) is considered the most effective form of pharmacological treatment for opioid use disorder (OUD). Previously, OAT medications were publicly subsidized in British Columbia by two PharmaCare plans: Fair PharmaCare, a voluntary, income-based plan providing partial coverage through a mix of deductible and co-payments; and the Income Assistance plan, offering full coverage of designated medications to registrants of social assistance. In response to the on-going opioid crisis, on February 1, 2017, BC added methadone and buprenorphine/naloxone used for OAT to a third plan – the Psychiatric Medications plan (Plan G), thereby expanding full coverage to an additional plan. Methods – Using administrative data, this thesis aimed to determine the impact of greater public coverage for OAT medications on BC residents living with OUD, with regard to utilization of, and retention in OAT, and the public and private financial consequences thereof, through an interrupted time series analysis (ITS) with control design. Use of the policy, and factors associated with its beneficiaries were similarly investigated, using ITS and logistic regression, respectively. Results – The addition of OAT medications to Plan G resulted in an increase in plan enrollments amongst BC residents previously subject to out-of-pocket costs for treatment. Results also suggest utilization and retention for buprenorphine/naloxone treatment increased. Methadone users benefitted from a small decrease in out-of-pocket expenses, while results for buprenorphine/naloxone were rendered inconclusive due to coinciding events. The removal of cost-sharing for non-OAT medications under Plan G resulted in an increase in PharmaCare expenditures, suggesting beneficiaries of the policy change also utilized other psychiatric medications available on the plan. Conclusion – The addition of OAT medications to Plan G was effective at providing greater drug coverage for a subset of BC’s population that was previously underserved by the PharmaCare system. Given the complexity of OUD, increases in utilization and retention for buprenorphine/naloxone treatment are encouraging. A reduction in client-costs for methadone should similarly be considered a success. With BC continuing to report record numbers of opioid-related deaths, the necessity of the income requirement for Plan G enrollment should be reconsidered if the goal is to reach the widest possible population.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Population and Public Health
Grantor dc:publisher
University of British Columbia
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Stucchi, Andrea
Contributors dc:contributor
  • Law, Michael R.

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/80101

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Stucchi, Andrea. Opioid agonist therapy under the PharmaCare psychiatric medications plan : utilization, retention, and financial consequences. master's thesis, University of British Columbia, 2021. http://hdl.handle.net/2429/80101